@article{JGO10240,
author = {Ying Zeng and Agnieszka A. Rucki and Xu Che and Lei Zheng},
title = {Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma},
journal = {Journal of Gastrointestinal Oncology},
volume = {8},
number = {3},
year = {2016},
keywords = {},
abstract = {Pancreatic adenocarcinoma is still widely considered as a deadly disease even though there are substantial therapeutic developments in the past decade. Using combinational chemotherapy regimens, represented by gemcitabine plus nab-paclitaxel and FOLFIRINOX, was able to improve overall survival in patients with advanced disease to a limited extent. It has been a challenge to develop targeted therapies that are focused on the neoplasm cells of pancreatic adenocarcinoma. Recently, targeting the stroma and immune compartments of pancreatic adenocarcinoma has shown promising results. The paradigm of biologics drug development therefore has been shifted by extending to these exciting areas. Although some of the preclinical and clinical researches in targeting the tumor microenvironment of pancreatic adenocarcinoma have shown promising results, others have resulted in controversial findings. Both comprehensive and in-depth researches on the basic science of the tumor microenvironment of pancreatic adenocarcinoma are thus warranted for the development of effective biologics that target the tumor microenvironment. Moreover, an ideal treatment for pancreatic adenocarcinoma shall be a combination of targeting both neoplastic cells and the tumor microenvironment.},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/10240}
}